Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 27, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - March 27, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/27/17 - "Hypotensive Lipid-Containing Biodegradable Intraocular Implants and Related Implants" in Patent Application Approval Process (USPTO 20170065612)
By a News Reporter-Staff News Editor at Clinical Trials Week A patent application by the inventor Hughes, Patrick M., filed on November 21, 2016, was made available online on March 16, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a company or instit
3/27/17 - "N-Ethyl-N-Phenyl-1,2-Dihydro-4,5-Di-Hydroxy-1-Methyl-2-Oxo-3-Quinolinecarb- Oxamide, Preparation and Uses Thereof" in Patent Application Approval...
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Ioffe, Vladimir; Ulanenko, Konstantin; Laxer, Avital; Safadi, Muhammad; Licht, Danit; Lovinger, Ioana; Fristedt, Ulf Tomas, filed on November 17, 2016, was made available online on March 16, 2017, according to news reporting originating from Washing
3/27/17 - "Pharmaceutical Composition" in Patent Application Approval Process (USPTO 20170065542)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors ST. LAURENT, Joseph P.; JONES, Gerald S.; BRESSE, David M., filed on September 9, 2016, was made available online on March 16, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has
3/27/17 - "Progress-Supressing Or Improving Agent for Chronic Kidney Disease" in Patent Application Approval Process (USPTO 20170065563)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventor IENAGA, Kazuharu, filed on February 25, 2015, was made available online on March 16, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Nippon Zoki Pharmaceutical Co.,
3/27/17 -
Facinghigh cost of health
But with a 45- count package of Claritin, a non-drowsy allergy treatment, costing $26 and the heartburn medicine Zantac costing $25 for a 65- count package, some people spend as much money out of pocket purchasing these drugs than similar prescription medicines. MedAssist's Over the Counter Medicine Give Away Day many arriving hours before the e
3/27/17 - 1 in 5 breast cancer patients could benefit from existing treatment, genetic study reveals
By a News Reporter-Staff News Editor at Clinical Trials Week Researchers from the Wellcome Trust Sanger Institute and their collaborators have discovered that a greater number of breast cancers are genetically similar to rarer cases with faulty BRCA1 or BRCA2 genes. The results published in Nature Medicine open up the possibility of up to 20 per
3/27/17 - 16 Years of Cultivation in the Pharma Industry
Being the leading pharma focused event for domestic and international pharmaceutical companies in Asia, CPhI& P-MEC China, is organized by Shanghai UBM Sinoexpo International Exhibition Co., Ltd. and China Medical and Health Import and Export Chamber of Commerce. With The Strong Power of "Expo+ Website". The event is a purchase matching service,
3/27/17 - Acadia Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Mar. 10, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acadia Pharmaceuticals Inc. was posted on March 10, 2017. The SEC file number is 0001415889-17-000405.. A U.S. Securities and Exchange Commission fil
3/27/17 - Acceleron Pharma Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Mar. 14, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acceleron Pharma Inc. was posted on March 14, 2017. The SEC file number is 0001179110-17-004588.. A U.S. Securities and Exchange Commission filing is
3/27/17 - Acelrx Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Mar. 10, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acelrx Pharmaceuticals Inc. was posted on March 10, 2017. The SEC file number is 0001437749-17-004197.. A U.S. Securities and Exchange Commission fil
3/27/17 - Achaogen Inc. Files SEC Form 10-K, Annual Report [Section 13 And 15(D), Not S-k Item 405] (Mar. 14, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Achaogen Inc. was posted on March 14, 2017. The SEC file number is 0001564590-17-004283.. A U.S. Securities and Exchange Commission filing is a forma
3/27/17 - Achaogen Inc. Files SEC Form 8-K, Current Report (Mar. 14, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Achaogen Inc. was posted on March 14, 2017. The SEC file number is 0001564590-17-004281.. A U.S. Securities and Exchange Commission filing is a forma
3/27/17 - Achaogen Inc. Files SEC Form S-8, Securities To Be Offered To Employees in Employee Benefit Plans (Mar. 14, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Achaogen Inc. was posted on March 14, 2017. The SEC file number is 0001564590-17-004297.. A U.S. Securities and Exchange Commission filing is a forma
3/27/17 - Acorda Therapeutics Inc. Files SEC Form SC 13G/A, Statement of Acquisition of Beneficial Ownership By Individuals (Mar. 10, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acorda Therapeutics Inc. was posted on March 10, 2017. The SEC file number is 0000891092-17-002024.. A U.S. Securities and Exchange Commission filing
3/27/17 - Acura Pharmaceuticals, Inc. Files SEC Form 25-NSE, Notification Filed By National Security Exchange To Report The Removal From Listing And...
Acura Pharmaceuticals, Inc. Files SEC Form 25- NSE, Notification Filed By National Security Exchange To Report The Removal From Listing And Registration of Matured, Redeemed Or Retired Securities. By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.
3/27/17 - Advaxis, Inc. Files SEC Form S-3/A, Registration Statement Under Securities Act of 1933 (Mar. 10, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Advaxis, Inc. was posted on March 10, 2017. The SEC file number is 0001493152-17-002326.. A U.S. Securities and Exchange Commission filing is a forma
3/27/17 - Aerie Pharmaceuticals Inc. Files SEC Form 10-K, Annual Report [Section 13 And 15(D), Not S-k Item 405] (Mar. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Aerie Pharmaceuticals Inc. was posted on March 9, 2017. The SEC file number is 0001628280-17-002421.. A U.S. Securities and Exchange Commission filin
3/27/17 - Aerie Pharmaceuticals Inc. Files SEC Form S-8, Securities To Be Offered To Employees in Employee Benefit Plans (Mar. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Aerie Pharmaceuticals Inc. was posted on March 9, 2017. The SEC file number is 0001193125-17-077014.. A U.S. Securities and Exchange Commission filin
3/27/17 - Agios Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Mar. 13, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agios Pharmaceuticals Inc. was posted on March 13, 2017. The SEC file number is 0001193125-17-079509.. A U.S. Securities and Exchange Commission fili
3/27/17 - Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne
DUBLIN and BOSTON, March 27, 2017/ PRNewswire/ Allergan plc,, a leading global pharmaceutical company and Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced that two Phase 3 trials of sarecycline for the treatment of moder
3/27/17 - Allergan's Trademark Application for "AUTYLA" Filed
By a News Reporter-Staff News Editor at Mental Health Weekly Digest According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "AUTYLA" by Susan J. Hinchey, representing Allergan. The owner/registrar information for this application is: Susan J. Hinchey, Allergan, 2525 Dupont Dr
3/27/17 - Allergan, Paratek Report Positive Results From Two Phase 3 Trials Of Sarecycline
WASHINGTON- Allergan plc and Paratek Pharmaceuticals Inc. announced that two Phase 3 trials of sarecycline for the treatment of moderate to severe acne met their 12 week primary efficacy endpoints. Based on these data, Allergan plans to file a New Drug Application to the U.S. Food& Drug Administration in the second half of this year. said David Nic
3/27/17 - Altasciences Clinical Research Companies Recognized for Leadership
By a News Reporter-Staff News Editor at Clinical Trials Week Altasciences Clinical Research proudly announces that its companies, Algorithme Pharma and Vince& Associates Clinical Research, have each been awarded multiple 2017 CRO Leadership Awards. This is the fourth consecutive year that Algorithme Pharma has been recognized by the industry.
3/27/17 - Amphastar Pharmaceuticals, Inc. Files SEC Form 8-K, Current Report (Mar. 13, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Amphastar Pharmaceuticals, Inc. was posted on March 13, 2017. The SEC file number is 0001297184-17-000003.. A U.S. Securities and Exchange Commission
3/27/17 - Ampio Pharmaceuticals, Inc. Files SEC Form 8-K, Current Report (Mar. 13, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Ampio Pharmaceuticals, Inc. was posted on March 13, 2017. The SEC file number is 0001193125-17-080560.. A U.S. Securities and Exchange Commission fil
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415